Citigroup Inc. Cuts Position in Integra LifeSciences Holdings Corporation (IART)

Citigroup Inc. decreased its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 86.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 6,717 shares of the life sciences company’s stock after selling 41,297 shares during the period. Citigroup Inc.’s holdings in Integra LifeSciences Holdings Corporation were worth $366,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Acrospire Investment Management LLC raised its holdings in Integra LifeSciences Holdings Corporation by 280.0% in the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after buying an additional 1,400 shares during the period. Riverhead Capital Management LLC raised its holdings in Integra LifeSciences Holdings Corporation by 49.9% in the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after buying an additional 799 shares during the period. LS Investment Advisors LLC raised its holdings in Integra LifeSciences Holdings Corporation by 4.6% in the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after buying an additional 111 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Integra LifeSciences Holdings Corporation by 8.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after buying an additional 218 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Integra LifeSciences Holdings Corporation by 56.9% in the first quarter. SG Americas Securities LLC now owns 4,294 shares of the life sciences company’s stock valued at $181,000 after buying an additional 1,557 shares during the period. Hedge funds and other institutional investors own 84.90% of the company’s stock.

Several research firms recently commented on IART. Oppenheimer Holdings, Inc. set a $60.00 price target on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a report on Saturday, June 24th. Jefferies Group LLC restated a “buy” rating and issued a $58.00 price target on shares of Integra LifeSciences Holdings Corporation in a report on Thursday, October 12th. Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corporation from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a report on Tuesday, October 10th. Cantor Fitzgerald started coverage on shares of Integra LifeSciences Holdings Corporation in a research note on Thursday, June 29th. They set an “overweight” rating and a $65.00 price objective on the stock. Finally, Raymond James Financial, Inc. lifted their price objective on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, July 27th. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $54.27.

ILLEGAL ACTIVITY WARNING: “Citigroup Inc. Cuts Position in Integra LifeSciences Holdings Corporation (IART)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/17/citigroup-inc-cuts-position-in-integra-lifesciences-holdings-corporation-iart.html.

Shares of Integra LifeSciences Holdings Corporation (IART) opened at 49.15 on Tuesday. The stock has a market cap of $3.84 billion, a price-to-earnings ratio of 59.94 and a beta of 0.72. Integra LifeSciences Holdings Corporation has a 1-year low of $37.71 and a 1-year high of $56.42. The stock’s 50 day moving average is $50.61 and its 200-day moving average is $49.50.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The firm had revenue of $282.16 million during the quarter, compared to analyst estimates of $283.58 million. During the same period in the previous year, the company earned $0.40 EPS. The company’s revenue for the quarter was up 13.2% on a year-over-year basis. On average, analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.91 EPS for the current year.

In other Integra LifeSciences Holdings Corporation news, Director Donald E. Morel, Jr. purchased 2,500 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was bought at an average cost of $49.29 per share, for a total transaction of $123,225.00. Following the completion of the acquisition, the director now directly owns 29,612 shares in the company, valued at $1,459,575.48. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Barbara B. Hill purchased 5,050 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were acquired at an average price of $49.33 per share, with a total value of $249,116.50. Following the

Other hedge funds and other institutional investors have also bought and sold shares of the company. Acrospire Investment Management LLC raised its holdings in Integra LifeSciences Holdings Corporation by 280.0% in the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after buying an additional 1,400 shares during the period. Riverhead Capital Management LLC raised its holdings in Integra LifeSciences Holdings Corporation by 49.9% in the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after buying an additional 799 shares during the period. LS Investment Advisors LLC raised its holdings in Integra LifeSciences Holdings Corporation by 4.6% in the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after buying an additional 111 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Integra LifeSciences Holdings Corporation by 8.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after buying an additional 218 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Integra LifeSciences Holdings Corporation by 56.9% in the first quarter. SG Americas Securities LLC now owns 4,294 shares of the life sciences company’s stock valued at $181,000 after buying an additional 1,557 shares during the period. Hedge funds and other institutional investors own 84.90% of the company’s stock.

Several research firms recently commented on IART. Oppenheimer Holdings, Inc. set a $60.00 price target on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a report on Saturday, June 24th. Jefferies Group LLC restated a “buy” rating and issued a $58.00 price target on shares of Integra LifeSciences Holdings Corporation in a report on Thursday, October 12th. Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corporation from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a report on Tuesday, October 10th. Cantor Fitzgerald started coverage on shares of Integra LifeSciences Holdings Corporation in a research note on Thursday, June 29th. They set an “overweight” rating and a $65.00 price objective on the stock. Finally, Raymond James Financial, Inc. lifted their price objective on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, July 27th. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $54.27.

ILLEGAL ACTIVITY WARNING: “Citigroup Inc. Cuts Position in Integra LifeSciences Holdings Corporation (IART)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/17/citigroup-inc-cuts-position-in-integra-lifesciences-holdings-corporation-iart.html.

Shares of Integra LifeSciences Holdings Corporation (IART) opened at 49.15 on Tuesday. The stock has a market cap of $3.84 billion, a price-to-earnings ratio of 59.94 and a beta of 0.72. Integra LifeSciences Holdings Corporation has a 1-year low of $37.71 and a 1-year high of $56.42. The stock’s 50 day moving average is $50.61 and its 200-day moving average is $49.50.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The firm had revenue of $282.16 million during the quarter, compared to analyst estimates of $283.58 million. During the same period in the previous year, the company earned $0.40 EPS. The company’s revenue for the quarter was up 13.2% on a year-over-year basis. On average, analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.91 EPS for the current year.

In other Integra LifeSciences Holdings Corporation news, Director Donald E. Morel, Jr. purchased 2,500 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was bought at an average cost of $49.29 per share, for a total transaction of $123,225.00. Following the completion of the acquisition, the director now directly owns 29,612 shares in the company, valued at $1,459,575.48. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Barbara B. Hill purchased 5,050 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were acquired at an average price of $49.33 per share, with a total value of $249,116.50. Following the completion of the acquisition, the director now owns 44,772 shares of the company’s stock, valued at $2,208,602.76. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 17,550 shares of company stock valued at $864,842. Corporate insiders own 21.50% of the company’s stock.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply